首頁 > 市場調查報告書 > 製藥

消化器孤兒藥

市場調查報告書

商品編碼

1471983

克隆氏症治療市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按藥物類別、配銷通路和地理位置

Crohn's Disease Therapeutics Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Distribution Channel, and Geography

出版日期: 2024年03月21日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄

克隆氏症治療市場預計將從2023年的96.8億美元成長到2031年的133.3億美元；預計2023年至2031年複合年成長率為4.1%。

克隆氏症是一種主要影響胃腸道的慢性發炎疾病。它通常會影響小腸的末端和大腸的起始部分。此疾病的特徵是消化道內壁炎症，導致腹痛、腹瀉和營養不良等症狀。克隆氏症治療市場規模的不斷成長歸因於西方國家（尤其是美國）疾病盛行率的不斷上升。此外，公司為保持競爭力而採取的策略性措施正在推動市場成長。醫療設備使用的顯著增加可能會在預測期內帶來新的克隆氏症治療市場趨勢。

精準醫學在克隆氏症治療中的滲透將為克隆氏症治療市場的成長創造機會。

精準醫學旨在根據每位患者的個別特徵（包括環境因素、基因組成、生活方式和其他變數）調整藥物治療。在克隆氏症治療中，精準醫療對於改善病患的治療效果和最大程度地減少不良反應具有重要的保證。在克隆氏症治療過程中，精準醫學有多種應用方式，例如基因分析、生物標記、藥物基因組學、標靶治療以及預測建模和機器學習。在基因分析中，基因定序技術使研究人員能夠發現與克隆氏症易感性和治療反應相關的特定遺傳變異。這將有助於他們選擇可能反應良好的藥物，並制定個人化的藥物計劃。

分析和檢查與克隆氏症活動相關的特定生物標記將幫助研究人員更好地了解疾病的嚴重程度並預測更好的結果。標靶治療是精準醫學的另一種方法，它選擇性地抑制導致克隆氏症發炎過程的特定分子。與傳統療法相比，這種個人化治療提高了效率並降低了全身毒性。

精準醫學進一步允許分層方法，根據既往疾病的特徵、生物標記和各種遺傳特徵將患者分層到不同的亞群。此類治療方法可以最佳化治療反應率、最小化治療反應率並改善克隆氏症治療的長期結果。

預測建模和機器學習技術可以分析複雜的資料集，以識別模式並預測疾病進展。這允許整合遺傳、臨床和其他相關資料。預測建模技術可以支援臨床醫生做出明智的治療決策並根據患者特徵進行個人化治療。

精準治療透過允許採用不同遺傳學、分子因素和臨床因素的個人化治療方法，在克隆氏症的治療方面具有巨大的潛力。這種治療在腸躁症中發揮重要作用，並最佳化了克隆氏症患者的治療效果。

精準醫學在治療克隆氏症方面取得了顯著進展，但許多目標仍未在基層實現。它需要龐大的資料、巨量資料、Hadoop等各種演算法工具以及先進的基礎設施才能有效實施。在精準醫學中實施先進的分析將為克隆氏症治療市場創造巨大的機會。

根據地理位置，克隆氏症治療市場分為北美（美國、加拿大和墨西哥）、歐洲（英國、德國、法國、義大利、西班牙、俄羅斯和歐洲其他地區）、亞太地區（中國、日本、印度、韓國、澳洲、東南亞和亞太地區其他地區）、中東和非洲（阿拉伯聯合大公國、沙烏地阿拉伯、南非以及中東和非洲其他地區）以及南美洲和中美洲（巴西、阿根廷、以及南美洲和中美洲其他地區）。由於生活方式因素，北美在 2023 年佔據全球克隆氏症治療市場的最大佔有率。然而，預計亞太地區 2023 年至 2031 年複合年成長率最高。 2022年，美國在北美克隆氏症治療市場中佔據最大佔有率。例如，2023年，美國食品藥物管理局（FDA）批准了第一個口服藥物－Rinvoq（upadacitinib）－用於治療中重度克隆氏症。 Rinvoq 旨在治療無法以阻斷腫瘤壞死因子 (TNF) 的候選藥物成功治療的成年患者。此外，2021年，艾伯維公司宣布啟動risankizumab治療克隆氏症的3期試驗。 Risankizumab 是一種人源化單株抗體，選擇性靶向白血球介素 23 (IL-23) 路徑。該試驗旨在評估 risankizumab 對中度至重度克隆氏症患者的療效和安全性。因此，上述因素支撐了市場的成長。

Crohn's disease is a chronic inflammatory condition primarily affecting the gastrointestinal tract. It commonly affects the end part of the small intestine and the beginning of the large intestine. The disease is characterized by the inflammation of the digestive tract lining, leading to symptoms such as abdominal pain, diarrhea, and malnutrition. The growing Crohn's disease therapeutics market size is attributed to the increasing prevalence of diseases in Western countries, particularly the US. In addition, strategic initiatives by companies to stay competitive are fueling market growth. A significant increase in the use of medical devices is likely to bring new Crohn's disease therapeutics market trends during the forecast period.

Penetration of Precision Medicine for the Treatment of Crohn's disease will Create an Opportunity for Crohn's disease therapeutics market growth.

Precision medicine aims to modify the medical therapy to the individual characteristics of each patient, including environmental factors, genetic makeup, lifestyle, and other variables. In Crohn's disease therapy, precision medicine holds significant assurance for improving the patient's results and minimizing the adverse effects. There are a few ways precision medicine is applied during Crohn's disease therapy, like genetic profiling, biomarker identification, pharmacogenomics, targeted therapies, and predictive modeling & machine learning. In genetic profiling, genetic sequencing technologies allow the researcher to discover specific genetic variations associated with Crohn's disease susceptibility and treatment response. This will help them choose the medicine that is likely to respond well and allow for a personalized medication plan.

Analyzing and examining the specific biomarkers associated with Crohn's disease activity will help researchers better access disease severity and predict better outcomes. Targeted therapy is another method in precision medicine that selectively inhibits specific molecules responsible for the inflammatory process responsible for Crohn's disease. Such personalized treatment enhanced efficiency and reduced systemic toxicity compared with conventional therapies.

Precision medicine further allowed the stratification method, which allowed the stratification of patients into distinct subgroups based on the prior diseases' characteristics, biomarkers, and various genetic signatures. Such treatment approaches can optimize the treatment response rate, minimize the treatment response rate, and improve long-term outcomes in the treatment of Crohn's disease treatment.

Predictive modeling and machine learning techniques can analyze complex data sets to identify patterns and predict disease progression. This allows the integration of genetic, clinical, and other relevant data. Predictive modeling techniques can support the clinician in making informed treatment decisions and personalizing the therapy based on patient characteristics.

Precision therapy holds huge potential for the treatment of Crohn's disease therapy by allowing individualized treatment approaches with diverse genetics, molecular factors, and contributing clinical factors. This treatment plays a prominent role in irritable bowel syndrome and optimizes patient outcomes in managing Crohn's disease.

Precision medicine has significantly progressed in treating Crohn's diseases, but many objectives are still unmet on the ground level. It requires a huge data bank, various algorithm tools like big data, Hadoop, and advanced infrastructure with which it can be implemented effectively. Implementing advanced analytics in precision medicine will create huge opportunities for treating Crohn's disease therapeutics market.

Based on geography, the Crohn's disease therapeutics market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, Southeast Asia, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). North America held the largest share of the global Crohn's disease therapeutics market in 2023 owing to the lifestyle factor. However, Asia Pacific is predicted to register the highest CAGR during 2023-2031. The US held the largest share of the Crohn's disease therapeutics market in North America in 2022. Market players in the US are adopting organic and inorganic strategies for Crohn's disease therapeutics market development. For instance, in 2023, the US Food and Drug Administration (FDA) approved the first oral pill-Rinvoq (upadacitinib)-to treat moderate-to-severe Crohn's disease. Rinvoq is meant to treat adult patients who could not be treated successfully with drug candidates blocking tumor necrosis factor (TNF). Furthermore, in In 2021, AbbVie Inc. announced the initiation of the Phase 3 trial of risankizumab for the treatment of Crohn's disease. Risankizumab is a humanized monoclonal antibody that selectively targets the interleukin-23 (IL-23) pathway. The trial is aimed at evaluating the efficacy and safety of risankizumab in patients with moderate-to-severe Crohn's disease. Thus, the factors mentioned above support the market growth.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Crohn's Disease Therapeutics Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Crohn's Disease Therapeutics Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Crohn's Disease Therapeutics Market - Global Market Analysis

6.1 Crohn's Disease Therapeutics - Global Market Overview
6.2 Crohn's Disease Therapeutics - Global Market and Forecast to 2031

7. Crohn's Disease Therapeutics Market - Revenue Analysis (USD Million) - By Drug Class, 2021-2031

7.1 Overview
7.2 Anti-inflammatory Drugs
7.3 Immune System Suppressors
7.4 Antibiotics
7.5 Biologics
7.6 Anti-diarrheal
7.7 Pain Relievers

8. Crohn's Disease Therapeutics Market - Revenue Analysis (USD Million) - By Distribution Channel, 2021-2031

8.1 Overview
8.2 Hospital Pharmacy
8.3 Retail Pharmacy
8.4 Online Pharmacy

9. Crohn's Disease Therapeutics Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

9.1 North America
- 9.1.1 North America Crohn's Disease Therapeutics Market Overview
- 9.1.2 North America Crohn's Disease Therapeutics Market Revenue and Forecasts to 2031
- 9.1.3 North America Crohn's Disease Therapeutics Market Revenue and Forecasts and Analysis - By Drug Class
- 9.1.4 North America Crohn's Disease Therapeutics Market Revenue and Forecasts and Analysis - By Distribution Channel
- 9.1.5 North America Crohn's Disease Therapeutics Market Revenue and Forecasts and Analysis - By Countries
  - 9.1.5.1 United States Crohn's Disease Therapeutics Market
    - 9.1.5.1.1 United States Crohn's Disease Therapeutics Market, by Drug Class
    - 9.1.5.1.2 United States Crohn's Disease Therapeutics Market, by Distribution Channel
  - 9.1.5.2 Canada Crohn's Disease Therapeutics Market
    - 9.1.5.2.1 Canada Crohn's Disease Therapeutics Market, by Drug Class
    - 9.1.5.2.2 Canada Crohn's Disease Therapeutics Market, by Distribution Channel
  - 9.1.5.3 Mexico Crohn's Disease Therapeutics Market
    - 9.1.5.3.1 Mexico Crohn's Disease Therapeutics Market, by Drug Class
    - 9.1.5.3.2 Mexico Crohn's Disease Therapeutics Market, by Distribution Channel

Note - Similar analysis would be provided for below mentioned regions/countries

9.2 Europe
- 9.2.1 Germany
- 9.2.2 France
- 9.2.3 Italy
- 9.2.4 Spain
- 9.2.5 United Kingdom
9.3 Asia-Pacific
- 9.3.1 Australia
- 9.3.2 China
- 9.3.3 India
- 9.3.4 Japan
- 9.3.5 South Korea
9.4 Middle East and Africa
- 9.4.1 South Africa
- 9.4.2 Saudi Arabia
- 9.4.3 U.A.E
9.5 South and Central America
- 9.5.1 Brazil
- 9.5.2 Argentina

10. Industry Landscape

10.1 Mergers and Acquisitions
10.2 Agreements, Collaborations, Joint Ventures
10.3 New Product Launches
10.4 Expansions and Other Strategic Developments

11. Competitive Landscape

11.1 Heat Map Analysis by Key Players
11.2 Company Positioning and Concentration

12. Crohn's Disease Therapeutics Market - Key Company Profiles

12.1 Abbvie, Inc.
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments

Note - Similar information would be provided for below list of companies